Correlation Engine 2.0
Clear Search sequence regions

  • behavior (1)
  • berbamine (7)
  • c Fos (1)
  • c57bl mice (1)
  • diet (1)
  • GTP (2)
  • gtpase (3)
  • hypothalamus (3)
  • lipid (1)
  • lipid homeostasis (1)
  • mice (7)
  • obese mice (2)
  • paraventricular nucleus (2)
  • Rab8a (6)
  • small gtpase (2)
  • weight (3)
  • Sizes of these terms reflect their relevance to your search.

    Small GTPase Rab8a is involved in fat-specific protein 27 (Fsp27) mediated lipid droplet accumulation in adipocytes. By screening inhibitors of Rab8a GTPase from a natural compound library, berbamine (BBM), a marketing drug for treatment of leukopenia in China, was identified to inhibit the activity of Rab8a GTPase and block the differentiation of 3T3-L1 adipocytes. Animal study showed that BBM could reduce body weight, improved glucose and lipid metabolic homeostasis in high-fat diet-induced obesity (DIO) C57BL/6 mice and db/db mice. Additional, BBM increased energy expenditure and inhibited food intake in mice but not in lean mice. Moreover, intracerebroventricular injection (i.c.v.) of BBM inhibited feeding behavior and increased c-Fos expression in paraventricular nucleus of the hypothalamus (PVH) of mice. Our data suggest that BBM may improve obesity through the inhibition of Rab8a GTPase activity and the activation of anorexigenic energy-sensing neuron in PVH. Copyright © 2022 Elsevier B.V. All rights reserved.


    Liufang Yin, Lijun Zhang, Lingling Luo, Yalei Liu, Fei Wang, Yaru Feng, Hongqing Wang, Yongli Han, Yingxuan Yan, Cheng Huang, Shengjie Fan. Berbamine reduces body weight via suppression of small GTPase Rab8a activity and activation of paraventricular hypothalamic neurons in obese mice. European journal of pharmacology. 2022 Feb 05;916:174679

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 34982965

    View Full Text